Travere Therapeutics Inc. | Small-cap | Healthcare
$21.64
2.32%
| Travere Therapeutics Stock Comparison:
Travere Therapeutics vs VertexTravere Therapeutics vs RegeneronTravere Therapeutics vs AdaptiveTravere Therapeutics vs ArcutisTravere Therapeutics vs Beam TherapeuticsTravere Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 81.7M
Gross Profit 77.1M 94.28%
Operating Income -42.7M -52.21%
Net Income -41.2M -50.44%
EPS (Diluted) $-0.47

Balance Sheet Metrics

Total Assets 548.8M
Total Liabilities 516.0M
Shareholders Equity 32.8M
Debt to Equity 15.72

Cash Flow Metrics

Operating Cash Flow -31.0M
Free Cash Flow -54.0M

Revenue & Profitability Trend

Travere Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i233.2M145.2M109.5M131.8M198.3M
Cost of Goods Sold i7.7M11.4M4.4M3.8M6.1M
Gross Profit i225.4M133.8M105.0M128.0M192.2M
Gross Margin % i96.7%92.1%96.0%97.1%96.9%
Operating Expenses
Research & Development i282.7M245.0M227.3M201.2M131.8M
Selling, General & Administrative i264.1M265.5M197.5M126.3M135.8M
Other Operating Expenses i----3.7M
Total Operating Expenses i546.8M510.5M424.9M327.4M271.2M
Operating Income i-321.4M-376.7M-319.8M-199.4M-75.4M
Operating Margin % i-137.8%-259.4%-292.2%-151.3%-38.0%
Non-Operating Items
Interest Income i17.8M21.8M6.3M2.0M5.0M
Interest Expense i11.2M11.3M11.0M19.7M19.0M
Other Non-Operating Income-5.8M-9.8M-6.6M231.0K-99.4M
Pre-tax Income i-320.5M-376.1M-331.2M-216.9M-188.8M
Income Tax i120.0K223.0K313.0K409.0K-19.4M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-321.5M-111.4M-278.5M-180.1M-169.4M
Net Margin % i-137.9%-76.7%-254.4%-136.6%-85.4%
Key Metrics
EBITDA i-263.3M-314.9M-291.8M-184.5M-44.4M
EPS (Basic) i$-4.08$-1.50$-4.37$-3.01$-3.56
EPS (Diluted) i$-4.08$-1.50$-4.37$-3.01$-3.56
Basic Shares Outstanding i7888886174267418637585155983228747539631
Diluted Shares Outstanding i7888886174267418637585155983228747539631

Income Statement Trend

Travere Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i58.5M58.2M61.7M165.8M84.8M
Short-term Investments i312.2M508.7M388.6M387.1M276.8M
Accounts Receivable i27.1M21.2M16.6M15.9M15.9M
Inventory i6.2M9.4M4.5M7.3M7.6M
Other Current Assets12.7M19.3M12.0M6.7M8.1M
Total Current Assets i416.7M616.8M486.4M582.8M410.4M
Non-Current Assets
Property, Plant & Equipment i00023.2M25.7M
Goodwill i104.8M105.3M97.9M149.3M155.1M
Intangible Assets i103.2M103.7M96.3M147.5M153.2M
Long-term Investments-----
Other Non-Current Assets53.8M42.2M59.0M11.1M7.8M
Total Non-Current Assets i177.5M172.2M186.2M193.8M197.0M
Total Assets i594.2M789.0M672.6M776.6M607.4M
Liabilities
Current Liabilities
Accounts Payable i23.5M41.7M17.3M15.1M12.1M
Short-term Debt i74.1M4.9M4.4M3.9M357.0K
Current Portion of Long-term Debt-----
Other Current Liabilities14.3M5.2M12.7M13.6M23.4M
Total Current Liabilities i200.8M177.9M142.2M124.1M92.7M
Non-Current Liabilities
Long-term Debt i327.5M399.9M403.1M258.1M243.7M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities6.8M8.5M9.4M72.0M59.9M
Total Non-Current Liabilities i334.3M410.2M487.6M350.4M303.6M
Total Liabilities i535.0M588.1M629.7M474.5M396.2M
Equity
Common Stock i9.0K7.0K6.0K6.0K5.0K
Retained Earnings i-1.4B-1.1B-1.0B-766.0M-585.9M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i59.1M200.8M42.9M302.1M211.2M
Key Metrics
Total Debt i401.6M404.8M407.5M262.0M244.0M
Working Capital i216.0M438.9M344.3M458.7M317.7M

Balance Sheet Composition

Travere Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-320.6M-376.3M-331.5M-217.3M-169.4M
Depreciation & Amortization i43.6M38.5M20.7M12.7M24.6M
Stock-Based Compensation i36.9M44.2M38.1M29.6M23.6M
Working Capital Changes i-28.8M-43.1M-16.1M65.5M-25.8M
Operating Cash Flow i-194.1M-338.6M-285.7M-94.0M-45.4M
Investing Activities
Capital Expenditures i--668.0K-191.0K-5.1M-6.8M
Acquisitions i-----
Investment Purchases i-125.8M-443.9M-385.4M-547.1M-215.0M
Investment Sales i326.3M334.6M382.0M433.6M273.5M
Investing Cash Flow i200.5M-110.0M-4.2M-118.6M51.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i00316.2M0-
Debt Repayment i00-211.3M0-
Financing Cash Flow i132.6M189.1M112.5M222.8M121.8M
Free Cash Flow i-338.7M-322.3M-214.8M-38.9M-162.6M
Net Change in Cash i139.1M-259.5M-177.4M10.3M128.1M

Cash Flow Trend

Travere Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.30
Forward P/E -18.08
Price to Book 59.95
Price to Sales 5.89
PEG Ratio 0.06

Profitability Ratios

Profit Margin -50.64%
Operating Margin -11.05%
Return on Equity -705.73%
Return on Assets -19.28%

Financial Health

Current Ratio 2.00
Debt to Equity 1,220.18
Beta 0.79

Per Share Data

EPS (TTM) $-2.02
Book Value per Share $0.37
Revenue per Share $3.95

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
tvtx1.9B-5.3059.95-705.73%-50.64%1,220.18
Vertex 101.6B28.195.9122.77%31.86%8.89
Regeneron 60.8B14.451.9915.34%31.37%9.04
Adaptive 2.0B-11.9010.88-57.60%-59.07%121.39
Arcutis 1.9B-14.6713.97-57.33%-35.40%79.27
Beam Therapeutics 1.9B-4.481.75-41.94%0.00%14.79

Financial data is updated regularly. All figures are in the company's reporting currency.